EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia

Akriti G Jain, Virginia O Volpe, Chen Wang, Somedeb Ball, Katherine Tobon, Onyee Chan, Eric Padron, Andrew Kuykendall, Jeffrey E Lancet, Rami Komrokji, David A Sallman, Kendra L Sweet

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05976-6 ↗

At a glance

Journal article in Annals of Hematology, 2024. Written by Akriti G Jain and 11 co-authors. Institution: Leukemia and Myeloid Disorders , Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. Jaina9@ccf.org. Major MEDLINE topics: Leukemia, Myeloid, Acute, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Antineoplastic Combined Chemotherapy Protocols. Cited 1 times so far (Crossref); 14 references. The full text is freely available (open access, CC BY 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Introduction

We aimed to compare outcomes of patients with AML treated with frontline hypomethylating agent and venetoclax (HMA + Ven) who achieved complete remission (CR), complete remission with partial hematologic recovery (CRh), complete remission with incomplete hematologic recovery (CRi), or morphologic leukemia-free state (MLFS) as defined by ELN 2022.

Methods

Patients with AML seen at Moffitt Cancer Center between 2018 and 2022 and treated with HMA + Ven were retrospectively evaluated.

Results

About 120 patients achieved blast clearance with best response of CR in 52 (43.3%), CRh in 22 (18.3%), CRi in 31 (25.8%) and MLFS in 15 (12.5%) patients. Greater proportion of patients with MLFS had a prior myeloid malignancy ( p = 0.003) and were treated with prior HMA ( p < 0.001). Patients that achieved MLFS as their best response had inferior OS compared to the CR/CRh/CRi cohort (8 months vs. 27 months; p < 0.001). RFS was also worse for the MLFS cohort.

Conclusion

To the best of our knowledge, this is the largest study analyzing differences in outcomes of AML patients treated with HMA + Ven based on best response. We noted that prior myeloid malignancy and use of HMA led to more MLFS as best response compared to CR/CRi. The OS and RFS were inferior for MLFS cohort.

Subjects

MeSH terms (MEDLINE)

Leukemia, Myeloid, AcuteSulfonamidesBridged Bicyclo Compounds, HeterocyclicAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedRetrospective StudiesAdultTreatment OutcomeRemission InductionAged, 80 and overDecitabine

Author keywords

AMLCRCRiComplete remissionELN 2022MLFSMorphological leukemia free state

Substances

venetoclaxSulfonamidesBridged Bicyclo Compounds, HeterocyclicDecitabine

Authors and institutions

  • Leukemia and Myeloid Disorders , Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. Jaina9@ccf.org.
  • Department of Malignant Hematology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
  • Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
  • Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Cite

APA

Jain, A. G., Volpe, V. O., Wang, C., Ball, S., Tobon, K., Chan, O., Padron, E., Kuykendall, A., Lancet, J. E., Komrokji, R., Sallman, D. A., & Sweet, K. L. (2024). Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-024-05976-6

Vancouver

Jain AG, Volpe VO, Wang C, Ball S, Tobon K, Chan O, et al. Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia. Annals of Hematology. 2024. doi:10.1007/s00277-024-05976-6

BibTeX
@article{Jain2024,
  author = {Jain, Akriti G and Volpe, Virginia O and Wang, Chen and Ball, Somedeb and Tobon, Katherine and Chan, Onyee and Padron, Eric and Kuykendall, Andrew and Lancet, Jeffrey E and Komrokji, Rami and Sallman, David A and Sweet, Kendra L},
  title = {Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05976-6}
}
Start for free →